Document
type: Class

Academic Article
type: Class

Continuant
type: Class

78782560
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-25T07:44:41
publisher: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
type: Document
label: RDF description of MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study - http://irises.unisr.it/resource/item/117641

Generically Dependent Continuant
type: Class

Article
type: Class

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
type: Generically Dependent Continuant
type: Continuant
type: Document
type: Academic Article
type: Entity
language: Inglese
type: Thing
type: Article
type: Information Content Entity
most specific type: Academic Article
related by: 78782560

Inglese
type: Language

Information Content Entity
type: Class